Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9852634 | 0.81 | TP53 (0.44) | THRBSMN1; SMN2TSHR | |
| SCHEMBL18504893 | 0.79 | THRB (0.39) | THRBCA14SMN1; SMN2TSHR | |
| SCHEMBL7250543 | 0.78 | DPP4 (0.38) | THRBCA14SMN1; SMN2TSHR | |
| SCHEMBL17000164 | 0.77 | SMN1; SMN2 (0.43) | THRBCA14SMN1; SMN2TSHR | |
| SCHEMBL4366391 | 0.73 | CA14 (0.38) | THRBCA14SMN1; SMN2TSHR | |
| SCHEMBL27866751 | 0.73 | CA14 (0.38) | THRBCA14SMN1; SMN2TSHR | |
| SCHEMBL10369163 | 0.73 | THRB (0.33) | THRBCA14SMN1; SMN2 | |
| SCHEMBL27576930 | 0.70 | — | — | |
| SCHEMBL27926754 | 0.69 | THRB (0.55) | THRBCA14SMN1; SMN2TSHR | |
| SCHEMBL27737037 | 0.69 | TP53 (0.49) | THRBSMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160220633-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| US-20160220633-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| US-9062092-B2 | Macrocyclic inhibitors of Flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9062092-B2 | Macrocyclic inhibitors of Flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2015-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160220633-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, ZC3HAV1, HCCS | THRB 3861/4885CA14 1713/4885SMN1; SMN2 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.